Beta BionicsBBNX
Recorded

Beta Bionics Stifel 2026 Healthcare Conference 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration31 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

See everyone. John Block with Stifel, day two of the healthcare conference. Welcome. I am happy to introduce the team from Beta Bionics, Stephen Feider, CFO, and Blake Beber, Manager of Investor Relations and Corporate Development. Guys, thanks for coming and joining us.

Stephen FeiderCFO

Wonderful to be here. Thanks, John.

Operator

We are going to hit on a bunch of different topics. You have a Mint box, and we will certainly talk about Mint for a little bit. I want to start with the 3Q26 recap. It was certainly a pretty good quarter, and new customer starts were in line. I think maybe there was some noise on 3D Intelligence, gross margin a little bit. Stock has been a bit weak since the quarter, so I am just going to toss it over to you, Steven, just your thoughts on what might be weighing on the stock a little bit. What has the investor feedback been since the quarter?

Stephen FeiderCFO

Well, 3D was the first public promise in terms of a timeline that we have missed. When we received Mint clearance at the same press release, we included this, really the introduction of 3D as a concept, and said that it would be commercializing by the end of 2026. Since then, subsequent to that, just prior to our Q3 earnings call, FDA told us to withdraw the submission, and we have had to resubmit it. We, in fact, since then have resubmitted it, which is good news, and I can get to that.

Stephen FeiderCFO

Okay. But that particular timeline, then we moved to mid-2027 for the 3D launch, with the potential that we could still launch it in Q4 2026.

Stephen FeiderCFO

What I think some investors have been asking us about is, okay, why did that happen? Again, as a new management team to operating a public company in the eyes of some investors, I think people maybe saw that as, "Do these guys understand what's going on with their dealings with FDA?" I will comment on that in a moment, but I think that has been some of the negative sentiment we have seen. In terms of what actually happened with 3D and why did we have to withdraw the application, not to get into any particular drama here, but really, there has been no questions from the FDA on the algorithms themselves that have us at all concerned.

Stephen FeiderCFO

We do not believe that the FDA is looking at the algorithm experiences that we are launching with 3D and sees any problem with them whatsoever. Where their questions have been and what we were unable to answer within the time parameter was on validation of the simulator. I will just say briefly on what we are talking about here with the simulator is, the FDA has been more open towards insulin dosing algorithm companies or insulin pump manufacturers creating enhancements or modifications to existing commercial algorithms using simulation, which is actually great for the industry. Predicated on that is that the FDA has to agree that whatever simulation tool you have built has been validated to represent a population of people who are living with diabetes.

Stephen FeiderCFO

In the case of Beta Bionics, we were fairly certain going through that process that FDA felt good about the simulation tool and validation of it. What happened late in the submission process was we got additional feedback on our simulator and the validation associated with it that we were unable to answer within the 90-day parameter, and they asked us to withdraw it. It was disappointing for us, but that is actually what happened. I believe we have now addressed their questions, and hopefully they will pick up right where they left off. If they do not, they certainly have statutorily the 90 days to re-look at it.

Operator

Okay. I think on the earnings call, you said you are going to submit by the middle of the quarter. Just to be clear, you have already resubmitted?

Stephen FeiderCFO

Yes. We have already resubmitted.

Operator

Okay. Just to go back to what you previously said, I think to give the management team, you guys credit, you said Mint by the end of 2027, then you pull it forward to 2Q, then you pull it forward to 1Q. You said you would find a way for type 2 adult label in sort of an efficient manner, and eventually you got there. Your point is with 3D Intelligence, it was maybe the first stumble with the agency, and people are a little bit focused on that in the near term.

Stephen FeiderCFO

Yeah. Not only that, it was our first time we have ever missed a date.

Stephen FeiderCFO

Yep that we have communicated publicly.

Operator

Okay. Okay. How about gross margin? In the quarter was below your expectations, but you said it was really a mix thing, right? Maybe just talk to us about what was de-stocked, which I think was the pumps, which was stocked, which I think was the supplies, and if there is like a normalized GM number that you might be able to give us for 3Q.

Stephen FeiderCFO

Mm-hmm. Yeah, this area, I haven't really gotten a ton of feedback from investors subsequent to the call because I think the communication was really clear as to exactly what happened, and it can be corroborated by the numbers that we share within our disclosure documents. Just reiterating briefly, you can review our transcript if you would like. We sold fewer iLet DME pumps in the third quarter relative to the second quarter, and we sold so few that I could even clarify it with this metric. Our DME suppliers purchased fewer DME pumps from Beta Bionics than what they sold to patients in the quarter, so there was a change in the inventory balance that was pretty significant from our DME distributors on iLet in DME, which is a very high margin revenue channel for us.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day